---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091766"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:54:17.285324+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# FibroGen Q2 net revenue +14% to $50.6M; cuts US workforce 75% after pancreatic trial failures

## Summary
- Net loss narrowed to $15.5M ($0.16/sh) from $87.7M ($0.90) YoY; revenue $50.6M (+14%).
- Raising 2024 roxadustat net product revenue guidance to $135-150M; China total net sales $92.3M (+21%).
- U.S. workforce cut ~75% after pamrevlumab misses endpoints in pancreatic cancer trials (PanCAN, LAPIS).
- Focusing on FG-3246 ADC for mCRPC; Phase 2 combo topline expected 1H 2025, monotherapy study start 1Q 2025.
- Cash, equivalents and AR $147.1M; runway into 2026; CIA approval in China 2H 2024 could trigger $10M milestone.

## SEC filing metadata
- accession: 0000950170-24-091766
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017024091766/0000950170-24-091766-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017024091766/fgen-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091766
- JSON: https://secwatch.observer/filing/0000950170-24-091766.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091766.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.